Prospective evaluation of cognitive function in patients with early breast cancer receiving adjuvant chemotherapy

Asia-Pacific Journal of Clinical Oncology

Volumn 3, Issue 3, 2007, Pages 125-133

  Ruzich, Michelle ^a   Ryan, Brigid ^a   Owen, Cathy ^a   Delahunty, Anne ^a   Stuart Harris, Robin ^a  

^a CANBERRA HOSPITAL   (Australia)

Author keywords

Adjuvant chemotherapy; Breast cancer; Cognitive function

Indexed keywords

CYCLOPHOSPHAMIDE; DEXAMETHASONE; EPIRUBICIN; FLUOROURACIL; LETROZOLE; METHOTREXATE; METOCLOPRAMIDE; ONDANSETRON; SEROTONIN ANTAGONIST; TAMOXIFEN;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; COGNITIVE DEFECT; COMBINATION CHEMOTHERAPY; CONSTIPATION; DIARRHEA; EARLY CANCER; FATIGUE; FEMALE; FOLLOW UP; HUMAN; LEARNING; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUROPSYCHOLOGICAL TEST; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSYCHOLOGIC TEST; PSYCHOLOGICAL RATING SCALE; QUALITY OF LIFE; VERBAL MEMORY;

EID: 34548218752     PISSN: 17437555     EISSN: 17437563     Source Type: Journal    
DOI: 10.1111/j.1743-7563.2007.00109.x     Document Type: Article

References (38)

1. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 2005; 365: 1687-717.
2. Anderson-Hanley C, Sherman ML, Riggs R, Agocha VB, Compass BE. Neuropsychological effects of treatments for adults with cancer: A meta-analysis and review of the literature. J Int Neuropsychol Soc 2003; 9: 967-82.
3. Ahles TA, Saykin AJ, Furstenberg CT et al. Neuropsychological impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma. Cognitive effects of standard-dose chemotherapy in patients with cancer. J Clin Oncol 2002; 20: 485-93.
4. Brezden CB, Phillips KA, Abdolell M et al. Cognitive function in breast cancer patients receiving adjuvant chemotherapy. J Clin Oncol 2000; 18: 2695-701.
5. Schagen SB, van Dam FS, Muller MJ, Boogerd W, Lindeboom J, Bruning PF. Cognitive deficits after postoperative adjuvant chemotherapy for breast carcinoma. Cancer 1999; 85: 640-50.
6. van Dam FS, Schagen SB, Muller MJ et al. Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: High-dose versus standard-dose chemotherapy. J Natl Cancer Inst 1998; 90: 210-18.
7. Wieneke MH, Dienst ER. Neuropsychological assessment of cognitive functioning following chemotherapy for breast cancer. Psychooncology 1995; 4: 61-6.
8. Wefel JS, Lenzi R, Theriault RL et al. The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma: results of a prospective, randomized longitudinal trial. Cancer 2004; 100: 2292-9.
9. Hurria A, Rosen C, Hudis C et al. Cognitive function of older patients receiving adjuvant chemotherapy for breast cancer: A pilot prospective study longitudinal study. J Am Geriatr Soc 2006; 54: 925-31.
10. Jenkins V, Shilling V, Deutsch G et al. A 3-year prospective study of the effects of adjuvant treatments on cognition in women with early stage breast cancer. Br J Cancer 2006; 94: 828-34.
11. Hurria A, Goldfarb S, Rosen C et al. Effect of adjuvant breast cancer chemotherapy on cognitive function from the older patient's perspective. Breast Cancer Res Treat 2006; 98: 343-8.
12. Bender CM, Sereika SM, Berga SL et al. Cognitive impairment associated with adjuvant chemotherapy in breast cancer. Psychooncology 2006; 15: 422-30.
13. Paganini-Hill A, Clark LJ. Preliminary assessment of cognitive function in breast cancer patients treated with tamoxifen. Breast Cancer Res Treat 2000; 64: 165-76.
14. Meyers CA. Neurocognitive dysfunction in cancer patients. Oncology (Williston Park) 2000; 14: 75-9.
15. Olin JJ. Cognitive function after systemic therapy for breast cancer. Oncology (Williston Park) 2001; 15: 613-18.
16. O'Shaughnessy JA. Chemotherapy-induced cognitive dysfunction: A clearer picture. Clin Breast Cancer 2003; 4 (Suppl. 2): S89-94.
17. Chochinov HM. Depression in cancer patients. Lancet Oncol 2001; 2: 499-505.
18. Lehto RH, Cimprich B. Anxiety and directed attention in women awaiting breast cancer surgery. Oncol Nurs Forum 1999; 26: 767-72.
19. Sherwin BB. Can estrogen keep you smart? Evidence from clinical studies. J Psychiatry Neurosci 1999; 24: 315-21.
20. Folstein MF, Folstein SE, McHugh PR. 'Mini-mental state'. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-98.
21. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983; 67: 361-70.
22. Aaronson NK, Ahmedzai S, Bergman B et al. The European Organization for Research and Treatment of Cancer QLQ-C30: A quality of life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993; 85: 365-76.
23. Schipper H, Clinch J, McMurray A, Levitt M. Measuring the quality of life of cancer patients: The FDnctional Living Index-Cancer: development and validation. J Clin Oncol 1984; 2: 472-83.
24. Nelson H, Willison J. National Adult Reading Test (NART), 2nd edn. The NFER-Nelson Publishing, Swindon 1991.
25. Wechsler D. Wechsler Adult Intelligence Scale, 3rd edn. Psychological Corporation, San Antonio, TX 1997.
26. Spreen OB. Neurosensory Center Comprehensive Examination for Aphasia (NCCEA). University of Victoria Neuropsychology Laboratory, Victoria, BC 1977.
27. Heaton RK, Chelune GJ, Talley JL, Kay GG, Curtiss G. Wisconsin card sorting test manual. Psychological Assessment Resources, Odessa, FL 1993.
28. Lezak M. Neuropsychological Assessment, 3rd edn. Oxford University Press, Oxford 1995.
29. Connors K. Connors' Continuous Performance Test Computer Program. Multi Health Systems, Toronto, ON 1992.
30. Reitan R. Trail Making Test. Manual for Administration and Scoring. Reitan Neuropsychological Laboratory, Tuscon, AZ 1971.
31. Shallice T. Specific impairments of planning. Philos Trans R Soc Lond B Biol Sci 1982; 298: 199-209.
32. Basso MR, Carona FD, Lowery N, Axelrod BN. Practice effects on the WAIS-III across 3- and 6-month intervals. Clin Neuropsychol 2002; 16: 57-63.
33. Tulsky DZ. WAIS-III/WMS-III Technical Manual. Psychological Corporation, San Antonio, TX 1997.
34. Basso MR, Bornstein RA, Lang JM. Practice effects on commonly used measures of executive function across twelve months. Clin Neuropsychol 1999; 13: 283-92.
35. Crawford JR, Stewart LE, Moore JW. Demonstration of savings on the AVLT and development of a parallel form. J Clin Exp Neuropsychol 1989; 11: 975-81.
36. Delaney RC, Prevey ML, Cramer J, Mattson RH, VA Epilepsy Cooperative Study # 264 Research Group. Test-retest comparability and control subject data for the Rey-Auditory Verbal Learning Test and Rey-Osterrieth/Taylor Complex Figures. Arch Clin Neuropsychol 1992; 7: 523-8.
37. Geffen GM, Butterworth P, Geffen LB. Test-retest reliability of a new form of the auditory verbal learning test (AVLT). Arch Clin Neuropsychol 1994; 9: 303-16.
38. Uchiyama CL, D'Elia LF, Dellinger AM et al. Alternate forms of the Auditory-Verbal Learning Test: Issues of test comparability, longitudinal reliability, and moderating demographic variables. Arch Clin Neuropsychol 1995; 10: 133-45.